NCT03688230 2020-03-18
AMELION
SFJ Pharmaceuticals, Inc.
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT00958477 2017-08-02
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01008475 2016-03-30
POSEIDON
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00848510 2015-12-14
EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01360840 2015-12-14
PERSEUS
EMD Serono
Phase 2 Completed